Article
Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 "Lynch-like" mismatch repair gene mutation.
Gynecologic oncology - 1 Oct 2023
Toboni Michael D, Wu Sharon, Farrell Alex, Xiu Joanne, Ribeiro Jennifer R, Oberley Matthew J, Arend Rebecca, Erickson Britt K, Herzog Thomas J, Thaker Premal H, Powell Matthew A
Abstract excerpt
OBJECTIVES: To identify differential survival outcomes and immune checkpoint inhibitor (ICI) response in MLH1 hypermethylated versus MLH1 mutated ("Lynch-like") endometrial tumors and determine whether their molecular profiles can elucidate the differential outcomes. METHODS: 1673 mismatch repair deficient endometrial tumors were analyzed by next-generation sequencing and whole transcriptome sequencing (Caris...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.